论文部分内容阅读
目的探讨使用孟鲁司特治疗过敏性紫癜(HSP)患儿对其T细胞亚群变化的影响。方法将2010年1月~2013年1月本院收治的120例过敏性紫癜患儿,随机分为为对照组60例和观察组60例,对照组行传统对症治疗,观察组在此基础上服用孟鲁司特进行治疗。治疗前后分别采集两组患儿血样对T细胞亚群含量进行测定。另同期选取40例正常儿童作为正常组。结果观察组患儿服用孟鲁司特治疗后其T细胞亚群CD4+T细胞、CD8+T细胞及CD4+/CD8+治疗前相比均有显著改善(P<0.05)。结论孟鲁司特能够调节过敏性紫癜患儿T细胞亚群的免疫作用,治疗过敏性紫癜有良好效果。
Objective To investigate the effects of Montelukast on T cell subsets in children with Henoch-Schonlein purpura (HSP). Methods From January 2010 to January 2013, 120 children with Henoch-Schonlein purpura were randomly divided into control group (60 cases) and observation group (60 cases). The control group received traditional symptomatic treatment. On the basis of this, Take montelukast for treatment. Before and after treatment were collected two groups of children with blood samples were measured T cell subsets. In the same period, 40 normal children were selected as the normal group. Results After treatment with montelukast, the children in observation group had significantly improved T cell subsets CD4 + T cells, CD8 + T cells and CD4 + / CD8 + before treatment (P <0.05). Conclusion Montelukast can regulate the immune function of T lymphocyte subsets in children with Henoch-Schonlein purpura and have good effect in the treatment of Henoch-Schonlein purpura.